Upper Respiratory Infection Drives Clinical Signs and Inflammatory Responses Following Heterologous Challenge of SARS-CoV-2 Variants of Concern in K18 Mice.

Alpha variant Delta variant K18-hACE2 mouse RNASeq SARS-CoV-2 challenge infection reinfection variants of concern

Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
11 04 2023
Historique:
received: 09 03 2023
revised: 30 03 2023
accepted: 06 04 2023
medline: 1 5 2023
pubmed: 28 4 2023
entrez: 28 4 2023
Statut: epublish

Résumé

The evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the emergence of several variants of concern (VOC) with increased immune evasion and transmissibility. This has motivated studies to assess protection conferred by earlier strains following infection or vaccination to each new VOC. We hypothesized that while NAbs play a major role in protection against infection and disease, a heterologous reinfection or challenge may gain a foothold in the upper respiratory tract (URT) and result in a self-limited viral infection accompanied by an inflammatory response. To test this hypothesis, we infected K18-hACE2 mice with SARS-CoV-2 USA-WA1/2020 (WA1) and, after 24 days, challenged with WA1, Alpha, or Delta. While NAb titers against each virus were similar across all cohorts prior to challenge, the mice challenged with Alpha and Delta showed weight loss and upregulation of proinflammatory cytokines in the URT and lower RT (LRT). Mice challenged with WA1 showed complete protection. We noted increased levels of viral RNA transcripts only in the URT of mice challenged with Alpha and Delta. In conclusion, our results suggested self-limiting breakthrough infections of Alpha or Delta in the URT, which correlated with clinical signs and a significant inflammatory response in mice.

Identifiants

pubmed: 37112926
pii: v15040946
doi: 10.3390/v15040946
pmc: PMC10144791
pii:
doi:

Substances chimiques

K-18 conjugate 0

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : HHSN272201400006C
Pays : United States
Organisme : NIAID NIH HHS
ID : 75N93021C00016
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI150745
Pays : United States

Références

Sci Rep. 2022 Feb 16;12(1):2628
pubmed: 35173254
Viruses. 2023 Feb 23;15(3):
pubmed: 36992320
Nature. 2022 Feb;602(7896):294-299
pubmed: 34818667
Sci Immunol. 2021 Apr 7;6(58):
pubmed: 33827897
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
Vaccines (Basel). 2022 Apr 14;10(4):
pubmed: 35455362
J Biomed Sci. 2022 May 3;29(1):27
pubmed: 35505345
Mol Med. 2021 Oct 18;27(1):129
pubmed: 34663207
Sci Transl Med. 2022 Apr 20;14(641):eabn6150
pubmed: 35258323
Sci Immunol. 2021 Dec 17;6(66):eabm3131
pubmed: 34699266
NPJ Vaccines. 2022 Feb 9;7(1):17
pubmed: 35140227
PLoS Biol. 2021 Dec 16;19(12):e3001384
pubmed: 34914685
Cell Host Microbe. 2021 May 12;29(5):744-746
pubmed: 33984277
PLoS Pathog. 2021 Jan 21;17(1):e1009233
pubmed: 33476327
Appl Microbiol Biotechnol. 2021 Dec;105(24):9035-9045
pubmed: 34755213
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
J Virol. 2021 Jun 10;95(13):e0223220
pubmed: 33827954
Front Immunol. 2021 Apr 26;12:668507
pubmed: 33981314
Nature. 2022 Jun;606(7914):576-584
pubmed: 35385861
Nature. 2021 Dec;600(7889):523-529
pubmed: 34634791
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Rev Microbiol. 2021 Mar;19(3):155-170
pubmed: 33116300
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
J Leukoc Biol. 2021 Jul;110(1):9-20
pubmed: 33404078
Nat Med. 2022 Mar;28(3):496-503
pubmed: 35090165
N Engl J Med. 2022 Apr 7;386(14):1377-1380
pubmed: 35297591
Comput Struct Biotechnol J. 2022;20:4501-4516
pubmed: 35965661
Cell. 2020 Oct 1;183(1):169-184.e13
pubmed: 32931734
Lancet. 2021 Mar 27;397(10280):1204-1212
pubmed: 33743221
J Virol. 2022 Mar 23;96(6):e0218421
pubmed: 35080423
Sci Transl Med. 2021 Sep;13(609):eabj0847
pubmed: 34376569
Sci Transl Med. 2022 Feb 02;14(630):eabm3302
pubmed: 34846168
PLoS One. 2012;7(9):e45842
pubmed: 23029269
Vaccines (Basel). 2022 Feb 23;10(3):
pubmed: 35334982
J Virol. 2007 Jan;81(1):20-9
pubmed: 16928755
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
Cytokine Growth Factor Rev. 2020 Jun;53:25-32
pubmed: 32446778
Am J Trop Med Hyg. 2020 Dec;103(6):2412-2418
pubmed: 33124544
Front Immunol. 2022 May 12;13:894534
pubmed: 35634338
Microorganisms. 2021 Aug 26;9(9):
pubmed: 34576716
Emerg Microbes Infect. 2022 Dec;11(1):2383-2392
pubmed: 36069511
Lancet Infect Dis. 2022 Jun;22(6):781-790
pubmed: 35366962
J Virol. 2021 Mar 3;95(10):
pubmed: 33658346

Auteurs

Jacob H Nichols (JH)

Department of Microbiology, Immunology and Biochemistry, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.

Evan P Williams (EP)

Department of Microbiology, Immunology and Biochemistry, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.

Jyothi Parvathareddy (J)

Regional Biocontainment Laboratory, University of Tennessee Health Science Center, Memphis, TN 38163, USA.

Xueyuan Cao (X)

Department of Health Promotion and Disease Prevention, College of Nursing, University of Tennessee Health Science Center, Memphis, TN 38163, USA.

Ying Kong (Y)

Department of Microbiology, Immunology and Biochemistry, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.

Elizabeth Fitzpatrick (E)

Department of Microbiology, Immunology and Biochemistry, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.

Richard J Webby (RJ)

St. Jude Children's Research Hospital, Memphis, TN 38163, USA.

Colleen B Jonsson (CB)

Department of Microbiology, Immunology and Biochemistry, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Regional Biocontainment Laboratory, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Institute for the Study of Host-Pathogen Systems, University of Tennessee Health Science Center, Memphis, TN 38163, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH